SAN
DIEGO, June 4, 2024 /PRNewswire/ -- Illumina Inc.
(NASDAQ: ILMN), a global leader in DNA sequencing and array-based
technologies, announced that it has completed integration of its
latest chemistry, XLEAP-SBS™, into all reagents for its
NextSeq™ 1000 and NextSeq 2000 next-generation
sequencing (NGS) instruments.
"We are excited to deliver for our NextSeq 1000/2000 customers
improved sequencing with faster run times, better quality, and
higher output—all at lower cost per kit," said Jason Johnson, head of Global Product Management
at Illumina. "XLEAP-SBS chemistry on NextSeq 1000/2000 will enable
labs to perform bigger NGS projects without raising the budget, and
facilitate greater adoption of multiomic approaches."
In March, the company launched its P4 flow cell (highest output
of 540 Gb) with XLEAP-SBS chemistry for the NextSeq 2000, and today
it announced that the XLEAP-SBS P1, P2, and P3 flow cells are all
now available. XLEAP-SBS chemistry is a faster, higher quality, and
more robust sequencing-by-synthesis chemistry that delivers
approximately 20% faster turnaround times.
Early-access customers have shared positive feedback on improved
quality, stability, and run times. Marc
Monot, PhD, head of Biomics at the Institut Pasteur, said,
"We were very happy with the quantity and quality of the reads. The
Q is very close to Q40 and the stability is a game changer for
Illumina. From the first base to the last base, [Illumina] improved
the quality of the run quite a lot."
The NextSeq 1000 and NextSeq 2000 Systems are flexible and
scalable mid-throughout sequencers that enable a range of
applications, including single-cell, whole-exome, and RNA
sequencing.
Use of forward-looking statements
This release contains forward-looking statements that involve
risks and uncertainties, including the expectation for lower costs
related to the storing and managing of genomic data costs. Among
the important factors that could cause actual results to differ
materially from those in any forward-looking statements are: (i)
challenges inherent in developing and launching new products and
services, including meeting manufacturing, quality, and performance
requirements; (ii) our ability to deploy new products, services,
and applications, and to expand the markets for our technology
platforms; and (iii) the acceptance by customers of our newly
launched products, which may or may not meet our and their
expectations once deployed, together with other factors detailed in
our filings with the Securities and Exchange Commission, including
our most recent filings on Forms 10-K and 10-Q, or in information
disclosed in public conference calls, the date and time of which
are released beforehand. We undertake no obligation, and do not
intend, to update these forward-looking statements, to review or
confirm analysts' expectations, or to provide interim reports or
updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as a global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit illumina.com and connect with us on X, Facebook,
LinkedIn, Instagram, TikTok, and YouTube
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Samantha Beal
PR@illumina.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/illumina-launches-latest-chemistry-across-most-popular-mid-throughput-sequencers-enabling-higher-quality-and-greater-speed-for-customers-at-lower-cost-302162971.html
SOURCE Illumina, Inc.